<DOC>
	<DOCNO>NCT01089608</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy T1225 eye drop versus placebo eye drop global ocular discomfort ( VAS ) .</brief_summary>
	<brief_title>Efficacy Safety Assessment Azyter® Eye Drops ( T1225 ) Patients With Blepharitis</brief_title>
	<detailed_description>Currently , topical antibiotic ointment use blepharitis . They provide prolong contact time lid margin little penetration eyelid tissue . Azithromycin eye drop may offer advantage preparation azithromycin achieves sustain high concentration various ocular tissue include lid margin . Patients treat 7 day ( 1 drop twice daily first day follow one drop daily 6 day ) follow period 2 week without treatment . This therapeutic scheme repeat two time . Efficacy evaluate change baseline ( Day 0 ) Day 63 Â± 3 Days global ocular discomfort evaluation ( VAS ) .</detailed_description>
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Povidone</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Diagnosis moderate severe chronic blepharitis ( posterior and/or anterior ) least one eligible eye Monophtalmia Eyelid dysfunction Facial paralysis . Severe dry eye syndrome . Ocular metaplasia . Filamentous keratitis Schirmer test &lt; 5 mm . Best far correct visual acuity &lt; 1/10 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Azyter patient affect chronic blepharitis .</keyword>
</DOC>